Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Option After CDK4/6: FDA Approves Giredestrant with Everolimus for ESR1-Mutated Breast Cancer

A New Option After CDK4/6: FDA Approves Giredestrant with Everolimus for ESR1-Mutated Breast Cancer
In this article

A New All-Oral Combination for Hormone Receptor-Positive Breast Cancer After CDK4/6 Inhibitors: Giredestrant and Everolimus

On 16 November 2026, the US Food and Drug Administration (FDA) approved the combination of giredestrant (Wilserdly) and everolimus (Afinitor) for ER-positive, HER2-negative advanced or metastatic breast cancer carrying an ESR1 mutation. The approval covers patients whose disease has progressed during or after endocrine therapy and is based on the randomised phase 3 evERA trial. In the 207 patients with an ESR1 mutation in this trial, the median time without disease progression was 10 months versus 5.5 months. Survival data are not yet mature. In this article, I explain the details of the approval, how to read the results, the side effects, the indirect comparison with the other FDA-approved options for the same patient group, and the situation in Türkiye. I had previously assessed the first results of the evERA trial in a separate article.

10 / 5.5mo · median progression-free survival in patients with an ESR1 mutation (combination / comparison)
41 / 15% · patients free of disease progression at 12 months
27 / 14% · marked tumour shrinkage (objective response rate)
207patients with an ESR1 mutation in evERA; the approval was granted for this group
Quick Answer · Physician's Summary
  • What was approved? Giredestrant 30 mg once daily with everolimus 10 mg once daily, for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer that has recurred during or after adjuvant endocrine therapy or progressed after at least one endocrine therapy in the metastatic setting. The ESR1 mutation must be shown with an FDA-approved blood test (FoundationOne Liquid CDx).
  • How effective is it? In patients with an ESR1 mutation, median progression-free survival was 10 months versus 5.5 months (HR 0.38). At 12 months, the proportion of patients still free of disease progression was 41% versus 15%. Survival data are not mature; the interim analysis shows a favourable trend (HR 0.62), but it is not statistically significant.
  • Side effects: The profile is largely due to everolimus: mouth sores (in about one in two patients), diarrhoea, anaemia, rash, fatigue and pneumonitis. Giredestrant can slow the heart rate. Dexamethasone mouthwash markedly reduces mouth sores.
  • Türkiye: As of November 2026, giredestrant is not licensed in Türkiye. Everolimus is licensed and reimbursed under certain conditions. Giredestrant can only be used through named-patient import of unlicensed medicines, without SGK reimbursement.

Why does this matter?

Hormone receptor-positive (ER-positive), HER2-negative breast cancer accounts for about two-thirds of all breast cancers (breast cancer guide, what is HER2?). In advanced disease, today's standard first-line treatment is endocrine therapy combined with a CDK4/6 inhibitor (CDK4/6 inhibitors). This treatment can work for years, but resistance eventually develops in most patients. "What should be done after a CDK4/6 inhibitor?" is one of the questions I hear most often in my clinic, and one whose answer is changing fastest (options after CDK4/6).

One of the most important causes of resistance is the ESR1 mutation. It develops in about 40% of patients treated with aromatase inhibitors for a long time; the oestrogen receptor then stays switched on even without oestrogen (resistance to endocrine therapy). Over the past three years, new-generation oral drugs targeting this mutation (oral SERDs) have been approved one after another. The approval of giredestrant and everolimus marks the first time one of these drugs has been approved together with an mTOR inhibitor, and it makes choosing the right sequence among the options even more important.

A first?
  • Yes: The first FDA approval for giredestrant.
  • Yes: The first approval of an oral SERD together with the mTOR inhibitor everolimus; an all-oral combination.
  • Yes (company statement): The first oral SERD combination to directly outperform standard endocrine therapy plus everolimus in a phase 3 trial in which all patients had previously received a CDK4/6 inhibitor.
  • No: It is not the first oral SERD (elacestrant, 2023). Nor is it the first SERD combination; in September 2026, camizestrant and imlunestrant were approved together with CDK4/6 inhibitors.
2002
Fulvestrant
The first SERD is approved; it is given by intramuscular injection.
2012
Everolimus + exemestane
With the BOLERO-2 trial, the mTOR inhibitor is approved in hormone receptor-positive breast cancer.
January 2023
Elacestrant
The first oral SERD approval, for patients with an ESR1 mutation.
2025-2026
New oral SERDs
Imlunestrant (September 2025), vepdegestrant (May 2026), camizestrant and the imlunestrant-abemaciclib combination (September 2026).
16 November 2026
Giredestrant + everolimus
The first approval of an oral SERD combined with an mTOR inhibitor. The FDA decision on giredestrant in early-stage (adjuvant) use is expected on 30 November 2026.

What is an ESR1 mutation?

ESR1 is the gene that encodes the oestrogen receptor. When this gene is mutated, the receptor stays switched on even without oestrogen and keeps driving the growth of the cancer cell. The mutation usually emerges during treatment with an aromatase inhibitor and reduces the effect of these drugs. It can be detected with a blood test (liquid biopsy).

An ESR1 mutation is rare at diagnosis; it develops during treatment as a resistance mechanism. This is why it is important to repeat the test when the disease progresses after a CDK4/6 inhibitor; the tissue result from diagnosis does not answer this question. The most commonly used method is a liquid biopsy that looks at tumour DNA in the blood (ctDNA in metastatic breast cancer). The same test can also assess other treatment targets such as PIK3CA, AKT1 and PTEN.

How do giredestrant and everolimus work?

Giredestrant is a new-generation oral SERD: it binds to the oestrogen receptor and causes the receptor to be broken down. The mutated receptor can also be targeted with this drug. Everolimus, in turn, shuts down a signalling pathway inside the cell called mTOR. When cancer cells become resistant to endocrine therapy, they often use this pathway as an escape route. Giving the two drugs together aims to shut down both the main growth signal and the escape route at the same time (what is everolimus?).

Figure 1 · Shutting down two pathways together

How giredestrant and everolimus work

Oestrogen receptor (ER)growth switch of hormone receptor-positive breast cancer ESR1 mutationthe receptor stays on even without oestrogen;aromatase inhibitors lose their effect Giredestrantbinds to the receptorand degrades it (SERD) Everolimusshuts down the mTORsignal, the escape route Both pathways are shut down togetherthe aim is to delay the development of resistance
How to read it: The oestrogen receptor is the main switch for cell growth in hormone receptor-positive breast cancer. With an ESR1 mutation, the receptor stays switched on even without oestrogen, and aromatase inhibitors lose their effect. Giredestrant binds to the receptor and breaks it down; everolimus shuts down the mTOR signal that the cancer cell uses as an escape route. The aim is to delay the development of resistance by shutting down both pathways together.

The evERA trial: who took part and what was compared?

evERA is an international, randomised, open-label phase 3 trial. A total of 373 patients with ER-positive, HER2-negative advanced breast cancer who had previously received endocrine therapy and a CDK4/6 inhibitor were divided into two groups: one group received giredestrant and everolimus, the other received the standard endocrine therapy chosen by the physician (mostly exemestane, less often fulvestrant or tamoxifen) plus everolimus (what is fulvestrant?). In other words, the comparison was between everolimus given with two different hormonal drugs. Premenopausal women and men also received injections to suppress ovarian or testicular function.

All patients had received a CDK4/6 inhibitor; about 47% had previously received fulvestrant, 77% had had at least one line of treatment for advanced disease, and 69% had visceral metastases such as in the liver or lungs. The trial had two co-primary endpoints: the time without disease progression (progression-free survival) in all patients and in patients with an ESR1 mutation.

Figure 2 · Design of the evERA trial

Phase 3, randomised, open-label

373 patients · ER-positive, HER2-negativeadvanced disease; all had received a CDK4/6 inhibitor1:1 randomised, open-label, phase 3 Giredestrant 30 mg+ everolimus 10 mgonce daily, by mouth183 patients Endocrine therapy(exemestane, fulvestrantor tamoxifen)+ everolimus · 190 pts ESR1-mutated subgroup: 207 patientsthe FDA approval was granted only for this group Primary endpoint: progression-free survivalin all patients and in ESR1-mutated patients separately
How to read it: 373 patients with ER-positive, HER2-negative advanced breast cancer who had previously received a CDK4/6 inhibitor were divided 1:1 into two groups. One group received giredestrant 30 mg and everolimus 10 mg daily; the other received the standard endocrine therapy chosen by the physician (exemestane, fulvestrant or tamoxifen) plus everolimus. 207 of the patients had an ESR1 mutation, and the FDA approval was granted only for this group. The primary endpoint was progression-free survival, assessed separately in all patients and in patients with an ESR1 mutation.

Results: how big is the difference?

In the 207 patients with an ESR1 mutation, median progression-free survival was 10.0 months with giredestrant and everolimus and 5.5 months in the comparison group (HR 0.38; 95% CI 0.27-0.54). This corresponds to a 62% relative reduction in the risk of disease progression or loss of life. In absolute terms, at 6 months the disease had not progressed in 66% of patients versus 38% in the comparison group; at 12 months, the figures were 41% versus 15%. Marked tumour shrinkage (objective response) was seen in 27% versus 14%, and the median duration of response was 14.9 months versus 7.3 months.

The benefit was seen regardless of whether exemestane or fulvestrant was used in the comparison group (HR 0.40 and 0.44, respectively, in exploratory analyses). The difference was also significant in all patients (8.8 versus 5.5 months; HR 0.56). However, in patients without an ESR1 mutation, the difference was small and not significant (5.7 versus 5.5 months; HR 0.84). For this reason, the FDA restricted the approval to patients with an ESR1 mutation.

evERA: the ESR1 mutation determines the benefit

Median progression-free survival, mo; giredestrant + everolimus (coloured) and endocrine therapy + everolimus (grey).

ESR1-mutated (207 patients)
9.99 mo
Comparison arm
5.45 mo
All patients (373)
8.77 mo
Comparison arm
5.49 mo
No ESR1 mutation
5.72 mo
Comparison arm
5.52 mo

HR 0.38 (95% CI 0.27-0.54) in the ESR1-mutated group; HR 0.56 in all patients; HR 0.84 (95% CI 0.59-1.18) in patients without an ESR1 mutation, where the difference was not significant (exploratory analysis). For this reason, the FDA restricted the approval to patients with an ESR1 mutation.

Overall survival

Overall survival data are not yet mature. In the interim analysis presented at ESMO 2025, median overall survival in patients with an ESR1 mutation had not yet been reached in the giredestrant arm and was 21.0 months in the comparison arm (HR 0.62; 95% CI 0.38-1.02). Although the trend is favourable, the confidence interval includes 1 and the result is not statistically significant. The FDA also described the survival data as "not mature" in the label. Because the trial was open-label, progression-free survival is based on investigator assessment; this is a limitation compared with blinded trials.

Quality of life

In the analysis presented at ESMO Breast Cancer 2026, overall quality of life was similar in the two groups. Deterioration in the ability to carry out daily activities occurred later in the giredestrant group (median 7.3 versus 4.6 months; HR 0.73). There were numerical differences in physical functioning and pain, but these were not significant.

Side effects: the main burden comes from everolimus

Because both groups received everolimus, the side effect profiles are similar. The most common side effects were mouth sores (stomatitis), rash, fatigue, diarrhoea, musculoskeletal pain, pneumonitis and nausea; the most common laboratory findings were anaemia and low lymphocyte and white blood cell counts (fatigue in cancer). Treatment discontinuation due to side effects was 17% in the giredestrant group and 11.8% in the comparison group; however, treatment duration was longer in the giredestrant group.

Side effects: similar in both arms

Giredestrant + everolimus (coloured) and endocrine therapy + everolimus (grey); proportion of patients, %.

Mouth sores (stomatitis)
47.2%
Comparison arm
48.9%
Diarrhoea
26.9%
Comparison arm
22.6%
Anaemia
23.6%
Comparison arm
21%
Slowing of the heart rate
3.8%
Comparison arm
0.5%
Stopping due to side effects
17%
Comparison arm
11.8%

Most side effects, such as mouth sores and pneumonitis, are due to everolimus; both arms received everolimus. 61% of patients used dexamethasone mouthwash to prevent mouth sores. Treatment duration was longer in the giredestrant arm (median 7.1 and 4.6 months), which may partly explain the discontinuation rate.

  • Mouth sores (stomatitis): The most common side effect of everolimus; it usually starts in the first weeks. In evERA, about 61% of patients used an alcohol-free dexamethasone mouthwash from the start of treatment. Grade 2 mouth sores occurred in 14% of those who used the mouthwash and 21% of those who did not; grade 3 mouth sores occurred in 1.8% versus 4.2%. For this reason, I recommend dexamethasone mouthwash to every patient starting this combination (everolimus and dexamethasone mouthwash).
  • Pneumonitis (lung inflammation): A side effect of everolimus that is usually mild and reversible; its frequency was similar to that in earlier everolimus trials. A new cough, shortness of breath or fever must always be reported (drug-related lung inflammation).
  • Slowing of the heart rate (bradycardia): A warning specific to giredestrant. In evERA it occurred in 3.8% of patients and was mild to moderate. Patients with a slow heart rate or taking medicines that slow the heart rate should be monitored more closely.
  • Others: Raised blood sugar and blood fats, susceptibility to infections and delayed wound healing are known side effects of everolimus. No visual disturbances (photopsia) were seen.
  • Pregnancy: Giredestrant can harm an unborn baby; effective non-hormonal contraception is needed during treatment and for 2 weeks after the last dose. Grapefruit should be avoided.

Other FDA-approved options for the same patient group

Since 2023, five different oral oestrogen receptor degraders have received FDA approval for ESR1-mutated, hormone receptor-positive advanced breast cancer. Technically, vepdegestrant degrades the receptor in a different way (PROTAC), but it is used for the same purpose in the clinic. These drugs have not been compared head to head; the table below gives only an indirect impression.

Drug (FDA approval) Trial For whom? PFS, mo (control); HR
Elacestrant, Orserdu (January 2023) EMERALD After CDK4/6, alone 3.8 (1.9); 0.55
Imlunestrant, Inluriyo (September 2025) EMBER-3 After endocrine therapy, alone 5.5 (3.8); 0.62
Vepdegestrant, Veppanu (May 2026) VERITAC-2 After endocrine therapy, alone 5.0 (2.1); 0.57
Camizestrant, Etcamah (September 2026) SERENA-6 When ESR1 emerges during first-line treatment, with CDK4/6 16.8 (9.2); 0.45
Imlunestrant + abemaciclib (September 2026) EMBER-3 After endocrine therapy 11.1 (5.5*); 0.53
Giredestrant + everolimus, Wilserdly (November 2026) evERA After endocrine therapy (all after CDK4/6 in the trial) 10.0 (5.5); 0.38

* Comparison: imlunestrant alone; exploratory analysis in the ESR1 subgroup. Camizestrant received accelerated approval.

Oral SERD trials in patients with an ESR1 mutation

Median progression-free survival, mo; experimental treatment (coloured) and comparison arm (grey).

evERA · giredestrant + everolimus
10 mo
Endocrine therapy + everolimus
5.5 mo
EMBER-3 · imlunestrant + abemaciclib
11.1 mo
Imlunestrant alone
5.5 mo
VERITAC-2 · vepdegestrant
5 mo
Fulvestrant
2.1 mo
EMERALD · elacestrant
3.8 mo
Standard endocrine therapy
1.9 mo

The evERA and EMBER-3 combinations show longer times than the single-agent SERD trials after a CDK4/6 inhibitor; however, the patient groups and the number of prior treatments differ. The EMBER-3 combination data in the ESR1 subgroup are exploratory. Comparisons across different studies are indirect; patient populations, prior treatments and follow-up times differ.

In my view, the most important message from this table is this: after a CDK4/6 inhibitor, median progression-free survival with oral SERDs given alone stays at around 4-5 months, whereas with combinations it appears to extend to 10-11 months. However, combinations mean more side effects. I have discussed elacestrant (Orserdu), imlunestrant (imlunestrant, imlunestrant and abemaciclib) and camizestrant (camizestrant and SERENA-6) in detail in separate articles. In the earlier BOLERO-2 trial, in which everolimus was used with exemestane before the CDK4/6 inhibitor era, median progression-free survival was 7.8 months versus 3.2 months; evERA shows that everolimus still has a place after CDK4/6 inhibitors when paired with the right hormonal drug.

The current landscape: when the disease progresses after CDK4/6

Treatment choice after a CDK4/6 inhibitor is now largely based on the molecular features of the tumour. Beyond ESR1, capivasertib and PI3K inhibitors stand out for patients with PIK3CA, AKT1 or PTEN alterations (capivasertib, PI3K inhibitors 2026), and PARP inhibitors for those with a BRCA mutation (olaparib). When the disease is progressing rapidly or organ function is threatened, chemotherapy or antibody-drug conjugates are preferred (trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan). I summarised the overall framework in my article on new options in hormone receptor-positive breast cancer.

Figure 3 · Choosing treatment after CDK4/6

A simplified approach based on molecular testing

Progression after a CDK4/6 inhibitorblood test (liquid biopsy) or tissue test:ESR1 · PIK3CA · AKT1 · PTEN · BRCA ESR1 mutationoral SERD aloneor combinations:giredestrant +everolimus;imlunestrant +abemaciclib PIK3CA / AKT1 / PTENcapivasertib,alpelisib oreverolimuscombinations BRCA mutationolaparib ortalazoparib Rapid progressionchemotherapy orantibody-drugconjugates The choice is personalisedprevious treatments, side effects, patient preferenceand whether the drug is available in Türkiye
How to read it: When the disease progresses after a CDK4/6 inhibitor, ESR1, PIK3CA, AKT1, PTEN and BRCA status is checked with a blood or tissue test. With an ESR1 mutation, an oral SERD can be used alone or in combinations such as giredestrant-everolimus or imlunestrant-abemaciclib. With a PIK3CA, AKT1 or PTEN alteration, capivasertib, alpelisib or everolimus combinations are options; with a BRCA mutation, olaparib or talazoparib. With rapid progression or a threat to organ function, chemotherapy or antibody-drug conjugates come to the fore. The choice is personalised according to previous treatments, the side effect profile, the patient's preference and whether the drug is available in Türkiye.

The situation in Türkiye

As of November 2026, giredestrant is not licensed in Türkiye. Everolimus (Afinitor and its generics) is licensed and, in hormone receptor-positive advanced breast cancer, is reimbursed together with exemestane under the conditions set out in the SUT; however, its combination with giredestrant is not covered. After the FDA approval, giredestrant can only be brought in with named-patient import authorisation from the Turkish Medicines and Medical Devices Agency (TİTCK); in this case, SGK reimbursement should not be expected (unlicensed imported medicines, medicines not reimbursed by SGK). Elacestrant, from the same group, was licensed in Türkiye in August 2025, but it is not reimbursed by SGK. Liquid biopsy tests for the ESR1 mutation are available in Türkiye; however, the test is often paid for by the patient. Clinical trials may also be an option for suitable patients (what is a clinical trial?).

Questions you can ask your doctor

  • My disease has progressed; has a blood or tissue test been done for ESR1, PIK3CA, AKT1, PTEN and BRCA?
  • If I have an ESR1 mutation, is an oral SERD alone or a combination more suitable for me?
  • How will we take precautions against the mouth sore, lung and blood sugar side effects of everolimus?
  • My heart rate is slow or I take heart medication; is giredestrant safe for me?
  • This drug is not licensed in Türkiye; how do the import process and its costs work, and is there a licensed alternative?
Common myths
  • "This combination is suitable for everyone with hormone receptor-positive breast cancer." No. The approval covers only patients with an ESR1 mutation; no significant difference was shown in those without the mutation.
  • "It has been proven to prolong survival." Not yet. It has been shown to delay disease progression; survival data are not mature.
  • "Because it is taken by mouth, it has few side effects." Wrong. Because of everolimus, mouth sores, diarrhoea, anaemia and pneumonitis are common; close monitoring is needed.
  • "My biopsy result from diagnosis shows my ESR1 status." Usually not. An ESR1 mutation mostly develops during treatment; the test needs to be repeated at the time of progression.
  • "The new drugs are clearly better than one another." Oral SERDs have not been compared head to head; the patient groups in the trials differ.

Frequently Asked Questions

What does the FDA approval of giredestrant and everolimus cover?
On 16 November 2026, the FDA approved giredestrant (Wilserdly) with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer. The disease must have recurred during or after adjuvant endocrine therapy or progressed after at least one endocrine therapy in the metastatic setting.
How effective were giredestrant and everolimus in the evERA trial?
In 207 patients with an ESR1 mutation, the median time without disease progression was 10 months versus 5.5 months (HR 0.38). At 12 months, the proportion of patients without disease progression was 41% versus 15%. Survival data are not yet mature.
What are the side effects of giredestrant and everolimus?
The most common side effects are mouth sores, rash, fatigue, diarrhoea, musculoskeletal pain, pneumonitis, nausea and anaemia; most are due to everolimus. Dexamethasone mouthwash reduces mouth sores. Giredestrant can slow the heart rate.
Is giredestrant available in Türkiye?
As of November 2026, giredestrant is not licensed in Türkiye. It can be obtained through named-patient import, but SGK reimbursement should not be expected. Everolimus, however, is licensed in Türkiye.

Glossary

ESR1 mutation
A change in the oestrogen receptor gene that causes the receptor to stay switched on even without oestrogen.
SERD
Selective oestrogen receptor degrader; a drug that binds to the oestrogen receptor and breaks it down.
Oral SERD
New-generation SERDs taken by mouth, such as elacestrant, imlunestrant, camizestrant and giredestrant.
mTOR inhibitor
A drug that shuts down the mTOR signalling pathway, which regulates cell growth; everolimus belongs to this group.
CDK4/6 inhibitor
Drugs that slow cell division: palbociclib, ribociclib and abemaciclib.
Liquid biopsy
A molecular test based on analysing tumour DNA in the blood.
Progression-free survival
The time a patient lives without the disease progressing.
Hazard ratio (HR)
The ratio of the risk of an event in two groups; a value below 1 favours the experimental treatment.
Stomatitis
Painful sores and inflammation inside the mouth.
Pneumonitis
Drug-related lung inflammation; it may present with cough and shortness of breath.

DROZDOGAN Academy Commentary

The approval of giredestrant and everolimus is the second combination approval aimed at overcoming the limited effect of single-agent oral SERDs in ESR1-mutated patients after endocrine therapy. The results are strong; however, the survival data and the side effect burden remain at the centre of the decision.

⚡ Why it matters

For a long time, median progression-free survival with endocrine therapy after a CDK4/6 inhibitor remained at around 2-5 months. In patients with an ESR1 mutation, evERA roughly doubled this time and offered a fully oral option.

✅ Strengths

Randomised phase 3 design; all patients treated after a CDK4/6 inhibitor; everolimus in the comparison arm as well, showing that the benefit comes from the SERD; a large effect size (HR 0.38); preserved quality of life; data on preventing mouth sores.

⚠️ Limitations

Open-label design and investigator assessment; immature survival data; no clear benefit in patients without an ESR1 mutation; the side effect burden of everolimus and a higher discontinuation rate; no head-to-head comparison with other oral SERD combinations.

🩺 In practice

In my patients whose disease progresses after a CDK4/6 inhibitor, I first assess ESR1 and other targets with a liquid biopsy. In patients with an ESR1 mutation who are in good general condition and can tolerate the side effects of everolimus, I see this combination as a strong option, and I start treatment together with dexamethasone mouthwash. In more frail patients, I may prefer an oral SERD alone. Because there is no licence or reimbursement in Türkiye, I make the decision with each patient after also discussing access and cost.

❓ Open questions

Will the survival benefit be confirmed? Is giredestrant-everolimus, imlunestrant-abemaciclib, or a SERD alone followed by a combination the better sequence? If giredestrant is approved for early-stage use (lidERA) on 30 November 2026, will the response to this drug in advanced disease change?

Bottom line: Giredestrant and everolimus is a new oral option that significantly delays disease progression in ESR1-mutated, hormone receptor-positive breast cancer after a CDK4/6 inhibitor. Its benefit is limited to patients with an ESR1 mutation; careful patient selection and attentive management of side effects will determine the success of this treatment.

Transparency note
  • This article was prepared in November 2026.
  • The approval information is based on sources reporting the FDA announcement and on the company press release. The median progression-free survival values in the FDA label are rounded (10 and 5.5 months); they were reported as 9.99 and 5.45 months in the congress presentation.
  • The evERA results are based on the ESMO 2025 and ESMO Breast Cancer 2026 presentations; I could not verify a full peer-reviewed journal publication of the trial at the time this article was prepared. Complete grade 3-4 side effect rates and the frequency of pneumonitis were not included in the disclosed sources.
  • Comparisons between trials are indirect. Please confirm licensing and reimbursement information for Türkiye against the current TİTCK and SGK lists.
  • The diagrams are simplified. The Academy commentary is my own. This article is not medical advice; make your treatment decisions together with your doctor.

References

  1. OncLive. FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer (16 November 2026). onclive.com
  2. CancerNetwork. FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer (November 2026). cancernetwork.com
  3. Genentech. FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer (16 November 2026). biospace.com
  4. Mayer EL, et al. evERA Breast Cancer: giredestrant plus everolimus vs standard endocrine therapy plus everolimus. ESMO Congress 2025, LBA16. targetedonc.com
  5. OncLive. Giredestrant/Everolimus Extends PFS for ER+/HER2– Advanced Breast Cancer (October 2025). onclive.com
  6. Martin M, et al. evERA: safety, stomatitis prophylaxis and quality of life. ESMO Breast Cancer 2026. oncodaily.com
  7. evERA Breast Cancer, NCT05306340. clinicaltrials.gov
  8. U.S. FDA. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (1 May 2026). fda.gov
  9. CancerNetwork. FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer (4 September 2026). cancernetwork.com
  10. OncLive. FDA Approves Imlunestrant Plus Abemaciclib for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer (18 September 2026). onclive.com
  11. Bidard FC, et al. Elacestrant versus standard endocrine therapy for ER-positive, HER2-negative advanced breast cancer: EMERALD. J Clin Oncol 2022;40:3246-3256. doi
  12. Baselga J, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer (BOLERO-2). N Engl J Med 2012;366:520-529. doi
  13. Rugo HS, et al. Prevention of everolimus-related stomatitis with dexamethasone mouthwash (SWISH). Lancet Oncol 2017;18:654-662. doi
  14. Genentech. FDA accepts New Drug Application for giredestrant in ER-positive early-stage breast cancer (lidERA; PDUFA 30 November 2026). biospace.com
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Option After CDK4/6: FDA Approves Giredestrant with Everolimus for ESR1-Mutated Breast Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy